Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer IndicationsElena Ardini, Arturo Galvani, Maria Menichincheri et al.|Molecular Cancer Therapeutics|2016Cited by 317
The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibitionElena Ardini, Antonella Isacchi, Andrea Borgia et al.|Molecular Oncology|2014Cited by 156
Abstract A232: In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori.Elena Ardini, Arturo Galvani, Maria Menichincheri et al.|Molecular Cancer Therapeutics|2011Cited by 20
In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori.Elena Ardini, Arturo Galvani, Maria Menichincheri et al.|Unknown|2011Cited by 11
Abstract 2092: The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models .Elena Ardini, Arturo Galvani, Maria Menichincheri et al.|Cancer Research|2013Cited by 10